LAMZEDE

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania.

Active ingredients

The drug LAMZEDE contains one active pharmaceutical ingredient (API):

1	Velmanase alfa UNII M91TG242P2 - VELMANASE ALFA
	Velmanase alfa is a recombinant form of human alpha-mannosidase. Velmanase alfa is intended to supplement or replace natural alpha-mannosidase, an enzyme that catalyses the sequential degradation of hybrid and complex high-mannose oligosaccharides in the lysosome, reducing the amount of accumulated mannose-rich oligosaccharides.
	Read more about Velmanase alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LAMZEDE Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB15		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	508520080013207, 508520080013307, 508520080013407
EE	Ravimiamet	1768158, 1768169, 1768170
FR	Base de données publique des médicaments	61080146
IL	מִשְׂרַד הַבְּרִיאוּת	8776
IT	Agenzia del Farmaco	046349015, 046349027, 046349039
LT	Valstybinė vaistų kontrolės tarnyba	1085340, 1085341, 1085342
PL	Rejestru Produktów Leczniczych	100403901
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65240002